Sanofi SA
SNY
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
Can you achieve global diversification with multinational companies?
A Morningstar report explores if the benefits of global investing can be achieved by investing in global companies trading on local exchanges.
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,703.70 | 9.10 | 0.10% |
| CAC 40 | 7,981.07 | 27.30 | 0.34% |
| DAX 40 | 23,278.85 | 115.93 | 0.50% |
| Dow JONES (US) | 45,752.26 | 386.51 | -0.84% |
| FTSE 100 | 9,527.65 | 20.24 | 0.21% |
| HKSE | 25,342.97 | 492.60 | -1.91% |
| NASDAQ | 22,078.05 | 486.18 | -2.15% |
| Nikkei 225 | 48,697.00 | 1,126.94 | -2.26% |
| NZX 50 Index | 13,354.80 | 84.60 | -0.63% |
| S&P 500 | 6,538.76 | 103.40 | -1.56% |
| S&P/ASX 200 | 8,430.50 | 14.00 | 0.17% |
| SSE Composite Index | 3,873.43 | 57.62 | -1.47% |